Who We Are
Going Beyond Binding for Protein Drug Discovery
The current state-of-the-art method for screening antibodies is phage display, which identifies candidate proteins that bind specified targets. Such binding centric drug discovery frequently misses designs with activities that depend on cellular machinery (degradation), endocytosis (transcytosis, FcRn recycling), and complex interactions with multiple targets on the cell surface and beyond. Our approach is to leverage spatial data and cell imaging to identify antibodies that can transport targets from one location in the cell to another, unlocking previously inaccessible therapeutic strategies.